Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Glioblastoma 5Glioma 3Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Rhabdoid Tumor 1Oligodendroglioma 1Melanoma 1Lymphoma 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

selinexor 1regorafenib 1pembrolizumab 1aflibercept 1Radiotherapy, Intensity-Modulated 1Protons 1Proton Pump Inhibitors 1Paclitaxel 1Nivolumab 1NEO212 1Ipilimumab 1IFL protocol 1Hydrocortisone 1Etoposide 1Endoscopic Mucosal Resection 1Cisplatin 1Carboplatin 1Bevacizumab 1Antineoplastic Protocols 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × selinexor × CNS × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡